Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Rodriguez

Showing results (201-210 of 231) with videos related to

Pageof 24
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2021
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM ExperiencePaula Rodriguez-Otero, Maialen Sirvent, Ana Pilar González-Rodríguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
Clinical Cardiology|February 19, 2025
"A Biomarker-Based Scoring System to Assess the Presence of Obstructive Coronary Artery Disease in Patients With Myocardial Infarction"María Jesús Espinosa Pascual, Jose Antonio Carnicero Carreño, Mariam El Assar, et al.
Journal of Neurointerventional Surgery|April 17, 2023
Influence of vascular imaging acquisition at local stroke centers on workflows in the drip-n-ship model: a RACECAT post hoc analysisAlan Flores, Alvaro Garcia-Tornel, Laia Seró, et al.
American Journal of Hematology|November 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapyAintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Nature Communications|June 23, 2026
Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment responseItziar Cenzano, Miguel Cócera, Marta Larrayoz, et al.
Transplantation and Cellular Therapy|March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple MyelomaBinod Dhakal, Nina Shah, Ankit Kansagra, et al.
Frontiers in Oncology|July 17, 2024
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapyJosé Luis Piñana, Lourdes Vazquez, Inmaculada Heras, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Pageof 24

Showing results (201-210 of 231) with videos related to

Sort By:
Pageof 24
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2021
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM ExperiencePaula Rodriguez-Otero, Maialen Sirvent, Ana Pilar González-Rodríguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
Clinical Cardiology|February 19, 2025
"A Biomarker-Based Scoring System to Assess the Presence of Obstructive Coronary Artery Disease in Patients With Myocardial Infarction"María Jesús Espinosa Pascual, Jose Antonio Carnicero Carreño, Mariam El Assar, et al.
Journal of Neurointerventional Surgery|April 17, 2023
Influence of vascular imaging acquisition at local stroke centers on workflows in the drip-n-ship model: a RACECAT post hoc analysisAlan Flores, Alvaro Garcia-Tornel, Laia Seró, et al.
American Journal of Hematology|November 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapyAintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Nature Communications|June 23, 2026
Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment responseItziar Cenzano, Miguel Cócera, Marta Larrayoz, et al.
Transplantation and Cellular Therapy|March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple MyelomaBinod Dhakal, Nina Shah, Ankit Kansagra, et al.
Frontiers in Oncology|July 17, 2024
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapyJosé Luis Piñana, Lourdes Vazquez, Inmaculada Heras, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Pageof 24